DNA data storage is the wildest number in Adam O’Dell’s Imperium pitch, and it deserves a close look on its own. The idea is to encode digital information into DNA molecules, storing files in the same material nature uses to store the instructions for life. The pitch attaches an eye-popping forecast to it, and our job is to separate the genuinely appealing technology from the headline number.

How DNA Data Storage Works

The concept leans on two properties DNA has in spades. First, density: DNA packs an enormous amount of information into a tiny volume, far more than any hard drive or flash chip. Second, durability: properly stored DNA can last for centuries, whereas magnetic and solid-state media degrade in years or decades. The process is to convert digital ones and zeros into the four-letter DNA code, synthesize the resulting strands, and later read them back out. It is real science, demonstrated in labs, and both big tech firms and government researchers are actively exploring it.

The 55,000% Claim

Here is where the pitch reaches for the sky. O’Dell says DNA data storage will grow “almost 55,000% over the next decade,” and he ties that figure to a Twist Bioscience spin-off in which Twist kept a 25% stake. We should be direct about what this number is. A 55,000% growth projection is an extrapolation so aggressive it functions as a headline rather than a forecast. The market it describes is still in the research stage and does not yet have a meaningful revenue base to grow from. When a market is near zero, almost any growth rate is possible on paper, which is exactly why the number should be treated as direction, not prediction.

The Genuine Appeal

None of that means the technology is fiction. The appeal is real: storing vast amounts of data in tiny volumes for centuries solves a problem data centers are just beginning to face as the world’s information keeps multiplying. That is why the field draws serious money and attention. The honest read is simply that this is a long-term research promise, not a near-term revenue stream, and the two are easy to confuse.

Where It Fits in the Pitch

DNA data storage is the far end of the same write step that powers the rest of the Imperium thesis. The company at the center of that thesis is Twist Bioscience, whose silicon-chip synthesis is what makes writing DNA, including DNA for storage, faster and cheaper over time. Twist posts 15 consecutive quarters of roughly 20% revenue growth and a market cap near $7.6 billion, so the core business is real even if the storage forecast is aspirational. For more on the company, see our Twist Bioscience stock explainer.

O’Dell’s track record is worth keeping in view. He began teasing Palantir in the spring of 2024 in the $20s, and it became the best-performing stock in the S&P 500 for the year. That is a real call. The DNA storage claim is a different kind of bet, one that will take years to play out. To understand the write step itself, start with our DNA synthesis explainer and our synthetic DNA explainer.

Why It Is Hard

The honest caveat is that DNA data storage still faces real technical hurdles. Writing DNA is slow and expensive compared to magnetic storage, and reading it back out takes specialized sequencing equipment. The gap between a lab demonstration and a product you could buy is large. None of that makes the idea wrong; it makes it early. The 55,000% forecast is really a statement of how far the technology has to go from a tiny starting base, not a promise about next year’s revenue.

The Twist Connection

The link to Twist Bioscience is a spin-off in which Twist kept a 25% stake plus royalty agreements. That structure gives Twist exposure to the upside if DNA data storage becomes a real market, without betting the whole company on it. It is a sensible way to hold an option on a long-shot idea while the core synthetic-DNA business keeps growing underneath.

The Presenter and the Offer

O’Dell is the chief investment strategist at Money & Markets and the founder of Green Zone Fortunes, and he also runs Cycle 9 Alert and 10X Profits. His method leans on the Green Zone Power Ratings, a quantitative screen that scores stocks on momentum, value, and volatility. The pitch is “Imperium: The No. 1 Investment for 2027,” $297 a year with a 30-day refund. His best recent call is documented: he began teasing Palantir in the spring of 2024 in the $20s, and it became the best-performing stock in the S&P 500 for the year.

The Honest Takeaway

The fair summary is this: DNA data storage is a real technology with a genuine reason to exist, and a forecast that runs far ahead of the evidence. It is the long-shot payoff in an already speculative pitch, and the right way to hold it is as a small, patient slice, not as the main reason to buy anything. The core of the Imperium thesis, writing DNA cheaper and faster, does not depend on the storage forecast coming true.

Ready to see the research? Click here to access Adam O’Dell’s report.


NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.